PIC Therapeutics
Modulating Oncogene Translation to Dramatically Improve Cancer Patient Outcomes
Modulating Oncogene Translation to Dramatically Improve Cancer Patient Outcomes
PIC Therapeutics is a biotechnology company that aims to revolutionize cancer treatment by developing a new generation of therapeutics based on RNA translation modulation. Founded in 2016, it is led by President and CEO Dr. Kathy Bowdish and is headquartered in the United States.
The company's pioneering work is based on the research of renowned Harvard Medical School professor, Dr. Gerhard Wagner, who specializes in protein structure and eukaryotic translation initiation factors. PIC Therapeutics translates these discoveries into small molecule precision therapeutics to benefit cancer patients.
With a focus on modulating the Pre-Initiation Complex (PIC) that drives mRNA translation, their precision-based therapeutics target the "master switch" of cancer signaling pathways, selectively blocking oncogene protein production. The $35.00 million Series A investment in October 19, 2022 by Advent Life Sciences, OrbiMed, Lumira Ventures, Harrington Discovery Institute at University Hospitals, and Belinda Termeer underscores the promising potential of their approach.
PIC Therapeutics' innovative strategy has the potential to simultaneously modulate multiple oncogenic drivers, opening avenues for a powerful new generation of cancer-treating therapeutics in the biotechnology and healthcare sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $35.00M | 5 |
|
19 Oct 2022 |
| Seed Round | $5.00M | 2 |
|
15 Apr 2020 |
No recent news or press coverage available for PIC Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
